Pfizer (PFE) Director Quincey James Receives Award

What Happened Quincey James, a member of Pfizer's Board of Directors, was granted 1,351.587 units (phantom shares) on 2026-09-25. The filing values each unit at $28.67, for a total award value of $38,750. This was an award of deferred director compensation (a derivative acquisition), not an open-market purchase or sale.

Key Details

• Transaction date and terms: 2026-09-25 — 1,351.587 units @ $28.67 per unit, total $38,750.
• Type: Award/Grant of derivative units (transaction code A).
• Shares/units owned after transaction: Not disclosed in the Form 4 filing.
• Footnotes: F1 — each unit represents one phantom share of common stock; F2 — units are deferred director compensation (including dividend equivalents) settled in cash or common stock at the director’s election after retirement from the Board.
• Filing timeliness: Form 4 was filed on 2026-09-29 (four days after the transaction date), which appears to be later than the standard two-business-day reporting deadline for Section 16 insiders.

Context These units are a deferred compensation award tied to Pfizer common stock (phantom shares) and do not reflect an immediate open-market purchase or sale. Because settlement can be in cash or stock after the director’s retirement, this grant is a routine board compensation action and should not be read as a direct trading signal about the director’s near-term view of the company.